| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Dec 6, 2015Virtual Press Office and PR Newswire: General Trade show news
Today, AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced preliminary data from the ongoing Phase 1/2b PCYC-1119 trial suggesting that the combination of ibrutinib (IMBRUVICA®)...
-
Dec 6, 2015Virtual Press Office and PR Newswire: General Trade show news
CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced an update on results from an investigator-sponsored Phase 2 trial of tosedostat – the company's investigational oral...
-
Dec 6, 2015Virtual Press Office and PR Newswire: General Trade show news
AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced results of a Phase 2, open label trial studying investigational compound venetoclax in patients with relapsed/refractory...
-
Dec 6, 2015Virtual Press Office and PR Newswire: General Trade show news
Data from the investigational, randomized, multi-center, open-label Phase 3 RESONATE™-2 (PCYC-1115) clinical trial show ibrutinib (IMBRUVICA®) was superior to chlorambucil in all efficacy...
-
Dec 6, 2015Virtual Press Office and PR Newswire: General Trade show news
Today, AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced the results of RESONATE™-2 (PCYC-1115), a Phase 3 clinical trial in which ibrutinib (IMBRUVICA®) significantly...
